Can you describe vitamin A metabolism, including its absorption, transport, hepatic storage, conversion to retinal and all‑trans‑retinoic acid, regulation, clinical signs of deficiency and toxicity, and recommended assessment and supplementation guidelines?

Vitamin A Metabolism

Vitamin A metabolism involves intestinal absorption of dietary retinoids and carotenoids, hepatic storage as retinyl esters, regulated release bound to retinol-binding protein, and tissue-specific conversion to the active metabolites retinal (for vision) and all-trans-retinoic acid (for gene regulation). 1

Absorption and Dietary Sources

Forms of Dietary Vitamin A

• Preformed vitamin A (retinol) is obtained from animal sources as retinyl esters, which are hydrolyzed to free retinol in the intestinal lumen before absorption 2, 3
• Provitamin A carotenoids (β-carotene, α-carotene, cryptoxanthin) are obtained from plant sources and require enzymatic conversion to retinol 1
• The bioconversion efficiency from provitamin A carotenoids ranges from 3.6:1 to 28:1, meaning substantially more carotenoid is needed compared to preformed retinol 1

Intestinal Absorption Mechanisms

• Retinol uptake occurs via saturable carrier-mediated transport at physiological doses, but switches to passive diffusion at pharmacological doses 1
• Provitamin A carotenoids are transported into intestinal mucosal cells by scavenger receptor class B type I (SR-BI) 3
• Within enterocytes, β-carotene is cleaved by beta-carotene 15'-monooxygenase (BCO1) to produce all-trans retinal, which is then reduced to all-trans retinol 2
• The absorbed retinol is re-esterified by lecithin retinol acyltransferase (LRAT) to form retinyl esters 2
• Retinyl esters are packaged into chylomicrons and absorbed via the lymphatic system, or retinol can be effluxed into portal circulation via the ABCA1 transporter 3

Absorption Efficiency

• Retinoids are well absorbed with 75-100% absorption efficiency, whereas carotenoid absorption varies greatly depending on food matrix and carotenoid type 1
• Fat-soluble vitamins including vitamin A follow lipids through the gastrointestinal tract, with absorption occurring primarily in the upper small intestine 1

Hepatic Storage

Storage Mechanisms

• Up to 90% or more of total body vitamin A is stored in the liver, primarily as retinyl esters 1
• Storage involves both hepatic parenchymal cells and non-parenchymal stellate cells 4
• The liver serves as the primary reservoir, maintaining vitamin A homeostasis and releasing retinol as needed by peripheral tissues 1, 4

Storage Forms

• Vitamin A is stored predominantly as retinyl esters (retinyl palmitate being the most common form) 2
• Hepatic stellate cells are the primary storage site for long-term vitamin A reserves 2

Transport in Circulation

Retinol-Binding Protein System

• Vitamin A is mobilized from liver stores and transported in plasma as retinol bound to retinol-binding protein (RBP), which is coupled to transthyretin (prealbumin) 1
• RBP is a negative acute phase protein, meaning its concentration falls during inflammation independent of true vitamin A status 1, 5
• Retinol mobilization is highly regulated by factors controlling the rates of RBP synthesis and secretion from the liver 4

Cellular Uptake

• Retinol enters peripheral cells via specific transmembrane transporters: STRA6 (stimulated by retinoic acid 6) in most peripheral tissues and RBPR2 (RBP4 receptor 2) in the retina and liver 2
• Delivery to target tissues may involve cell surface receptors for RBP 4

Alternative Transport

• Retinoic acid is transported in plasma as the anion bound to serum albumin (non-specific binding) 4
• Carotenoids are transported by lipoproteins (density <1.21 g/ml), particularly low-density lipoproteins 4

Conversion to Active Metabolites

Retinal Formation (for Vision)

• Within cells, all-trans retinol is oxidized to all-trans retinal by retinol dehydrogenases 6
• In the retina, all-trans retinal is isomerized to 11-cis-retinal, which serves as the visual chromophore in the phototransduction cycle 2, 3

Retinoic Acid Formation (for Gene Regulation)

• All-trans retinal is further oxidized to all-trans-retinoic acid by retinal dehydrogenases 6
• Retinoic acid functions as a prohormone and the primary physiologically active form regulating gene expression 1, 6
• Both all-trans-retinoic acid and 9-cis-retinoic acid serve as ligands for nuclear receptors 1

Nuclear Receptor Activation

• Retinoic acid binds to two families of nuclear receptors: retinoic acid receptors (RAR) and retinoid X receptors (RXR) 1, 6
• These receptors form heterodimers within the RAR/RXR family and with vitamin D receptors or steroid/thyroid hormone receptors 1
• The activated receptor complexes regulate expression of more than 500 target genes controlling cellular growth, differentiation, immune function, reproduction, and development 1, 6

Intracellular Binding Proteins

• Tissues contain soluble binding proteins: cellular retinol-binding protein (CRBP) for retinol and cellular retinoic acid-binding protein (CRABP) for retinoic acid 4
• These proteins facilitate intracellular transport and metabolism of retinoids 4

Regulation of Vitamin A Metabolism

Homeostatic Control

• Serum retinol concentrations remain homeostatically controlled until liver stores are severely depleted, making serum levels insensitive for detecting early deficiency 5
• Provitamin A carotenoids (β-carotene) are subject to negative feedback control, making them safer than preformed retinol as they cannot cause toxicity 1, 7

Factors Affecting Metabolism

• Zinc deficiency impairs RBP synthesis and vitamin A mobilization from the liver 1, 5
• Protein malnutrition reduces RBP production and vitamin A transport 5
• Inflammation reduces RBP release from the liver and causes redistribution of the prealbumin-RBP complex from plasma 5

Clinical Signs of Deficiency

Ocular Manifestations

• Night blindness (nyctalopia) is the earliest clinical sign of deficiency 5
• Xerophthalmia progresses through stages: conjunctival xerosis, Bitot's spots, corneal xerosis, corneal ulceration, and keratomalacia (corneal necrosis) leading to blindness 1, 5

Systemic Manifestations

• Impaired epithelial cell differentiation and maintenance affecting mucous membranes 1
• Compromised immune function (particularly T-cell function) leading to increased infection susceptibility 1
• Impaired growth and development in children 1
• In cystic fibrosis patients, deficiency is associated with poorer clinical status, impaired lung function, and increased pulmonary exacerbations 1

High-Risk Conditions

Clinical conditions associated with vitamin A deficiency include: infection (sepsis, HIV), burns, mechanical ventilation, steroid use, hepatobiliary dysfunction, renal failure, trauma, hematooncological conditions, intestinal dysfunction (abetalipoproteinemia), protein-energy malnutrition, zinc deficiency, and cystic fibrosis 1

Clinical Signs of Toxicity

Acute Toxicity

• Occurs with doses >150,000 μg (>500,000 IU) 8
• Presents with increased intracranial pressure (pseudotumor cerebri), headache, nausea, vomiting, vertigo, blurred vision, and muscular incoordination 7, 8

Chronic Toxicity

• Occurs with prolonged intake of approximately 30,000 μg/day (>100,000 IU/day) 8
• Presents with bone abnormalities, dermatitis, alopecia, ataxia, muscle pain, cheilitis, skin and vision disorders, and hepatocellular necrosis 7, 8

Teratogenicity

• Retinol is a potent teratogen and must be avoided in women of childbearing potential 7
• Both hypervitaminosis A and hypovitaminosis A can cause harm to mother and fetus during pregnancy 1, 7
• The therapeutic window between deficiency and toxicity is narrow, requiring careful dosing 1, 7

Biochemical Markers of Toxicity

• Retinyl esters >250 nmol/L in serum suggest hypervitaminosis A 5
• The risk of toxicity is higher with water-miscible and water-soluble forms than with oil-based supplements 1

Assessment Guidelines

Serum Retinol Measurement

• Serum retinol measured by HPLC is the primary laboratory test, with normal range 1.05-2.8 mmol/L (300-800 mg/L) for children >6 months and adults 1, 5
• Deficiency thresholds: <0.7 mmol/L (200 mg/L) indicates deficiency; <0.35 mmol/L (100 mg/L) indicates severe deficiency with depleted liver stores 1, 5
• In premature infants, <0.7 mmol/L indicates deficiency and <0.35 mmol/L indicates severe deficiency 1

Retinol-Binding Protein

• RBP <0.48 mmol/L is associated with severe vitamin A deficiency 1, 5
• Under stress conditions, serum retinol is unreliable; use the RBP/transthyretin ratio instead 1

Functional Assessment

• Relative Dose Response (RDR) test: administer 450-1000 μg retinyl palmitate orally and measure serum retinol at baseline and 5 hours post-dose; RDR ≥14-20% indicates deficiency and depleted liver stores 5
• Plasma RBP response and relative rise in serum retinol concentration following intramuscular vitamin A administration are useful functional tests 1

Adjusting for Inflammation

• Measure C-reactive protein (CRP) and/or alpha-1-acid glycoprotein (AGP) simultaneously to adjust for inflammation, as serum retinol and RBP decrease with inflammation independent of true vitamin A status 5
• During acute infection, serum retinol concentrations fall and should not be used to assess vitamin A status 1

Monitoring Frequency

• Annual serum monitoring once normal vitamin A levels are achieved 1
• For high-risk patients (post-bariatric surgery, malabsorption): initial assessment at 3,6, and 12 months, then at least annually 5
• For cystic fibrosis patients: evaluate plasma levels 3-6 months after initiation or change in enzyme and vitamin supplementation 1

Sample Handling

• Retinoids are susceptible to photo-degradation and oxidation; samples require antioxidants, light protection, and proper temperature handling 5

Supplementation Guidelines

Pediatric Parenteral Nutrition

• Preterm infants: 700-1500 IU/kg/day (227-455 μg/kg/day) 1
• Term infants: 150-300 μg/kg/day (2300 IU/day) 1
• Older children: 150 μg/day 1
• Parenteral lipid-soluble vitamins should be given with lipid emulsion to prevent substantial losses (>60% loss occurs with water-soluble solutions) 1, 8

Prophylactic Supplementation in High-Risk Areas

• Infants <6 months: 100,000 IU orally every 3 months 8
• Infants 6-12 months: 100,000 IU orally every 3 months 8
• Children 12 months to <5 years: 200,000 IU orally every 3 months 8
• Post-partum mothers (breastfeeding): 200,000 IU within 2 months after delivery to enrich breast milk 8

Treatment of Clinical Deficiency (Xerophthalmia)

• Standard emergency regimen for children: 200,000 IU orally on day 1,200,000 IU on day 2, and 200,000 IU at 1-4 weeks 8
• Infants <12 months: half-strength doses (100,000 IU) on the same schedule 8
• Adults: 10,000-25,000 IU oral vitamin A daily for 1-2 weeks, then recheck levels at 3 months 8

Cystic Fibrosis Patients

• Retinol (preformed): start low, adapt rapidly to target normal serum reference range 1
• Beta-carotene (provitamin A): 1 mg/kg/day (maximum 50 mg/day) for 12 weeks, followed by maintenance dose (maximum 10 mg/day) 1
• Monitor serum levels to guide initial and continuing doses; beta-carotene is safer due to negative feedback control 1

Lactating Women

• The European Food Safety Authority recommends 1300 μg retinol equivalent/day for lactating women, related to transfer into breast milk 7
• The WHO does not recommend routine vitamin A supplementation in postpartum women in developed countries with adequate dietary access 7

Pregnancy Considerations

• Assess vitamin A intake and blood levels before conception or early in pregnancy 1
• Aim to achieve normal range of serum retinol concentrations (as advised by laboratory) 1
• Women of childbearing potential should limit intake to <10,000 IU/day to avoid teratogenicity 8

Documentation

• Record every vitamin A dose on the child's growth chart 8
• Document administration in medical records 7

Common Pitfalls to Avoid

• Do not use water-based solutions for parenteral vitamin A—use lipid emulsions exclusively to prevent >60% drug loss 1, 8
• Do not rely on serum retinol during acute illness or inflammation; use RBP/transthyretin ratio or wait until inflammation resolves 1, 5
• Do not fail to distinguish between preformed vitamin A (retinol) and provitamin A (beta-carotene) when calculating total intake 7
• Do not ignore dietary sources when prescribing supplements to avoid toxicity 1, 7
• Do not under-dose infants <12 months with clinical deficiency; they require exactly half the standard treatment dose (100,000 IU), not a lower amount 8
• Do not confuse prophylactic dosing (100,000-200,000 IU every 3 months) with therapeutic dosing (200,000 IU on consecutive days) 8
• Do not use serum retinol alone in patients with zinc or protein deficiency, as these confound measurements 5
• Do not assess vitamin A status during acute infection when serum retinol falls as an acute phase response 1, 5
• For treatment-resistant deficiency, refer to specialists for assessment and consideration of intramuscular vitamin A injections 8